OBREFCO Trademark
Trademark Overview
On Wednesday, June 29, 2022, a trademark application was filed for OBREFCO with the United States Patent and Trademark Office. The USPTO has given the OBREFCO trademark a serial number of 97480903. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Monday, June 8, 2026. This trademark is owned by Bristol-Myers Squibb Company. The OBREFCO trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
General Information
| Serial Number | 97480903 |
| Word Mark | OBREFCO |
| Filing Date | Wednesday, June 29, 2022 |
| Status | 734 - FIFTH EXTENSION - GRANTED |
| Status Date | Monday, June 8, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 23, 2023 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, July 19, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543
US |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10016
US |
Trademark Events
| Event Date | Event Description |
| Saturday, July 2, 2022 | NEW APPLICATION ENTERED |
| Tuesday, July 19, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, October 4, 2022 | ASSIGNED TO EXAMINER |
| Friday, October 14, 2022 | NON-FINAL ACTION WRITTEN |
| Friday, October 14, 2022 | NON-FINAL ACTION E-MAILED |
| Friday, October 14, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, April 12, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, April 12, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, April 13, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, April 14, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 3, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 23, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 23, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 18, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, August 2, 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, August 2, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, August 2, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, January 2, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, January 2, 2024 | SOU EXTENSION 1 FILED |
| Tuesday, January 2, 2024 | SOU EXTENSION 1 GRANTED |
| Thursday, January 4, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, July 8, 2024 | SOU TEAS EXTENSION RECEIVED |
| Monday, July 8, 2024 | SOU EXTENSION 2 FILED |
| Monday, July 8, 2024 | SOU EXTENSION 2 GRANTED |
| Monday, July 8, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, January 7, 2025 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, January 7, 2025 | SOU EXTENSION 3 FILED |
| Tuesday, January 7, 2025 | SOU EXTENSION 3 GRANTED |
| Tuesday, March 4, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, June 24, 2025 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, June 24, 2025 | SOU EXTENSION 4 FILED |
| Tuesday, June 24, 2025 | SOU EXTENSION 4 GRANTED |
| Tuesday, June 24, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, January 12, 2026 | SOU TEAS EXTENSION RECEIVED |
| Thursday, June 4, 2026 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Sunday, January 11, 2026 | SOU EXTENSION 5 FILED |
| Monday, June 8, 2026 | SOU EXTENSION 5 GRANTED |
| Monday, June 8, 2026 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
